Guest guest Posted June 17, 2006 Report Posted June 17, 2006 http://www.zengen.com/technology.htm#infective CZEN 002 has been the focus of the Company's research into the control of infection. Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth, and interference with cell metabolism, all of which can give rise to a broad range of life-threatening diseases and disorders. CZEN 002 has been shown to directly kill pathological fungi, gram- negative and gram-positive bacteria and to inhibit replication of HIV- 1, the virus responsible for AIDS. Therapeutic Peptide Portfolio Anti-Inflammatory Activity Anti-Infective Activity Competitive Advantages over Glucocorticoid Steroids Recent Patents Partnering & #945;-MSH, a molecule which occurs naturally in the body, modulates inflammatory and immune responses. Dr. Lipton, Zengen's President and CEO, first demonstrated that & #945;-MSH possesses anti- inflammatory properties and discovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the & #945;-MSH peptide. These discoveries led to the development of Zengen's proprietary peptide molecules, including the lead small-molecule CZEN 002. A synthetic octapeptide, CZEN 002 has broad application as an anti-inflammatory and anti-infective prescription pharmaceutical agent. Zengen and its European partner are currently conducting Phase IIb clinical trials with CZEN 002 in vaginal yeast infection, vulvovaginal candidiasis (VVC), and developing the molecule for treatment of inflammation. Mechanism of Action Defined: Zengen has already established the mechanism of anti-inflammatory action of its molecules: inhibition of the activation of nuclear factor kappa B (NF & #954;, an intracellular substance essential to production of pro-inflammatory cytokines that mediate inflammation. With regard to antifungal activity, Zengen's studies suggest that CZEN 002 has a unique mechanism of action, one that has not been described previously. In brief, the action appears to be receptor-mediated, one that occurs via induction of the second messenger cAMP within the fungal cell, resulting in the death of the cell from within. The establishment of mechanisms of action has been advantageous with regard to regulatory affairs for Zengen's lead molecules. Back to top Zengen's scientists have established the effects of the CZEN molecules in animal models of all of the established forms of inflammation, including: Acute inflammation in the skin Delayed hypersensitivity reactions (allergies) Chronic inflammation associated with arthritis and inflammatory bowel disease. Systemic inflammation, including sepsis, septic shock and endotoxemia Inflammation of the central nervous system, that is believed to underlie aspects of multiple sclerosis, Alzheimer's disease and stroke Back to top CZEN 002 has been the focus of the Company's research into the control of infection. Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth, and interference with cell metabolism, all of which can give rise to a broad range of life-threatening diseases and disorders. CZEN 002 has been shown to directly kill pathological fungi, gram- negative and gram-positive bacteria and to inhibit replication of HIV- 1, the virus responsible for AIDS. Back to top The Zengen peptides share anti-inflammatory activity with the widely- used glucocorticoids, representatives of the steroid hormones. The peptides, however, have competitive advantages over glucocorticoids because they have beneficial effects on additional clinical symptoms that often occur simultaneously in disease and injury: inflammation, infection, and fever. That is, the peptides are more beneficial than glucocortcoids which are commonly used to reduce inflammation, but have little or no effect on fever and can actually promote growth of microbes. Lead Product Candidate: Advanced Clinical Stage Zengen scientists have developed two lead molecules, CZEN 002 and CZEN 001, to leverage the remarkable properties of & #945;-MSH and to avoid potential side effects of using the entire & #945;-MSH molecule. These two lead molecules have several basic advantages over the parent & #945;-MSH molecule including: better efficacy, higher specificity of biological action, greater stability, smaller size resulting in lower manufacturing costs, and a strong intellectual property position. Examples of Zengen Targets Vaginal Candidiasis (VVC): Drug Resistance Rising VVC is a common gynecological infection with thirteen million cases occurring in the US every year, resulting in 5 to 10 million physician visits. Seventy-five percent of all women will experience a VVC episode in their lifetime and 5% will experience recurrent or chronic VVC (³4 episodes/year). The overall VVC market size is almost $6 billion per year. Standard prescription-based therapies are imidazole-based drugs. Infections that do not respond to treatment with this class of drugs are becoming more common, especially in HIV-infected women receiving long-term antifungal therapy. A disadvantage of current therapies is that none are fungicidal agents, directly killing Candida fungi. The azole drugs are all fungistatic agents that simply reduce the replication of the fungi and the woman must rely on her own immune system to control the fungal burden. In addition, azole-resistant Candida species complicate therapy and prolonged exposure to drugs like fluconazole can shift the predominant vaginal yeast from C. albicans to more intrinsically azole-resistant species. There has been a recent epidemiological shift to non-C. albicans strains being the cause of infection. In the early 1990's, Candida albicans accounted for more than 80% of all yeast infections while today, more than 40% is due to non-C. albicans isolates. CZEN 002 is well positioned to effectively treat VVC, especially in patients with chronic VVC or with azole-resistant C. albicans infections. Topical Fungal Infections: High Prevalence Topical fungal infections are a common occurrence and every year approximately 33 million cases of superficial dermatophyte infections occur in the US. Some of the most frequent types are: tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). Tinea unguium (nail infection) affects 1 to 3% of the US population. Use of CZEN 002 to treat topical fungal infections is a logical extension of the VVC indication. Both applications target fungal agents using the existing CZEN 002 topical formulation. Atopic Dermatitis: High Unmet Medical Need in Large Population Atopic dermatitis, often called eczema, is a chronic disease characterized by inflammation of the skin which becomes extremely itchy, red, swollen, crusty and scaly. Atopic dermatitis is a very common disease and accounts for 10 to 20% of all dermatology visits. Approximately 20% of children experience symptoms of atopic dermatitis and more than 15 million adults in the United States have the disease. It is estimated that greater than $1 billion per year is spent on atopic dermatitis treatments. The incessant itch and work loss in adult life is a great burden. The VVC and pruritus clinical studies demonstrated the anti-itch properties of the Zengen peptides. The CZEN 002 topical formulation developed for the VVC application can be leveraged to pursue the large opportunity in atopic dermatitis. Back to top September 06, 2005 Use of a polypeptide for treatment of pruritis in animals. This patent, derived from Zengen's original studies on inflammation and itch in humans, has opened a new treatment for control of pruritis in companion and production animals. This technology is open for partnering. May 03, 2005 Antimicrobial amino acid sequences derived from alpha melanocyte stimulating hormone. The novel molecules covered under this patent have potent effects against fungal infection. This technology is open to partnering. May 01, 2005 Use of KPV tri-peptide for dermatological disorders. This patent forms the basis for multiple clinical applications currently under development. October 12, 2004 Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus. This Zengen technology is available for licensure. October 05, 2004 A uro-genital treatment system patent protects Zengen technologies for vaginal yeast infection applications. Zengen plans to out-license this technology after further progress of the Phase IIb trial. August 24, 2004 A compound method of treatment for fungal pathologies of the oral cavity. This application of Zengen's technologies is also open for license or other forms of partnering. Back to top Please send partnering or licensing inquiries to: info@.... Or contact: Lipton, PhD President and Chief Executive Officer Phone: (818) 887-8688 Fax: (818) 887-3883 Email: jlipton@... Back to top © COPYRIGHT ZENGEN, INC. | Website Maintained & Hosted by Majestic Imaging. > > Melanocyte stimulating hormone Dr. Shoemaker is the one I know tests his > patients for it. So far it is not available in the US. - a > > > > > > There was an article about the drug being developed by Palatin Technologies > (PT-141) to enhance sexual functioning in New York Magazine: > > http://newyorkmetro.com/lifestyle/sex/annual/2005/15061/ > > > > alpha MSH replacement medicine, legally obtained in other countries, still > not approved by the FDA. > > Called Melanotan it is supposed to prevent skin cancer, elevate blood > levels of MSH (It is made by the Australian Co., Epi Tan) and in the case of > Melanotan II to act as a sort of Viagra in men. (This is made by the NJ > firmof Palatin Technologies) > Quote
Guest guest Posted June 17, 2006 Report Posted June 17, 2006 , thanks for sending this link on alpha MSH. Now if I can just figure out the product to buy in China. I can see why Dr. Shoemaker is excited about the use of alpha MSH. a http://www.zengen.com/technology.htm#infective CZEN 002 has been the focus of the Company's research into the control of infection. Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth, and interference with cell metabolism, all of which can give rise to a broad range of life-threatening diseases and disorders. CZEN 002 has been shown to directly kill pathological fungi, gram- negative and gram-positive bacteria and to inhibit replication of HIV- 1, the virus responsible for AIDS. Therapeutic Peptide Portfolio Anti-Inflammatory Activity Anti-Infective Activity Competitive Advantages over Glucocorticoid Steroids Recent Patents Partnering & #945;-MSH, a molecule which occurs naturally in the body, modulates inflammatory and immune responses. Dr. Lipton, Zengen's President and CEO, first demonstrated that & #945;-MSH possesses anti- inflammatory properties and discovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the & #945;-MSH peptide. These discoveries led to the development of Zengen's proprietary peptide molecules, including the lead small-molecule CZEN 002. A synthetic octapeptide, CZEN 002 has broad application as an anti-inflammatory and anti-infective prescription pharmaceutical agent. Zengen and its European partner are currently conducting Phase IIb clinical trials with CZEN 002 in vaginal yeast infection, vulvovaginal candidiasis (VVC), and developing the molecule for treatment of inflammation. Mechanism of Action Defined: Zengen has already established the mechanism of anti-inflammatory action of its molecules: inhibition of the activation of nuclear factor kappa B (NF & #954;, an intracellular substance essential to production of pro-inflammatory cytokines that mediate inflammation. With regard to antifungal activity, Zengen's studies suggest that CZEN 002 has a unique mechanism of action, one that has not been described previously. In brief, the action appears to be receptor-mediated, one that occurs via induction of the second messenger cAMP within the fungal cell, resulting in the death of the cell from within. The establishment of mechanisms of action has been advantageous with regard to regulatory affairs for Zengen's lead molecules. Back to top Zengen's scientists have established the effects of the CZEN molecules in animal models of all of the established forms of inflammation, including: Acute inflammation in the skin Delayed hypersensitivity reactions (allergies) Chronic inflammation associated with arthritis and inflammatory bowel disease. Systemic inflammation, including sepsis, septic shock and endotoxemia Inflammation of the central nervous system, that is believed to underlie aspects of multiple sclerosis, Alzheimer's disease and stroke Back to top CZEN 002 has been the focus of the Company's research into the control of infection. Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth, and interference with cell metabolism, all of which can give rise to a broad range of life-threatening diseases and disorders. CZEN 002 has been shown to directly kill pathological fungi, gram- negative and gram-positive bacteria and to inhibit replication of HIV- 1, the virus responsible for AIDS. Back to top The Zengen peptides share anti-inflammatory activity with the widely- used glucocorticoids, representatives of the steroid hormones. The peptides, however, have competitive advantages over glucocorticoids because they have beneficial effects on additional clinical symptoms that often occur simultaneously in disease and injury: inflammation, infection, and fever. That is, the peptides are more beneficial than glucocortcoids which are commonly used to reduce inflammation, but have little or no effect on fever and can actually promote growth of microbes. Lead Product Candidate: Advanced Clinical Stage Zengen scientists have developed two lead molecules, CZEN 002 and CZEN 001, to leverage the remarkable properties of & #945;-MSH and to avoid potential side effects of using the entire & #945;-MSH molecule. These two lead molecules have several basic advantages over the parent & #945;-MSH molecule including: better efficacy, higher specificity of biological action, greater stability, smaller size resulting in lower manufacturing costs, and a strong intellectual property position. Examples of Zengen Targets Vaginal Candidiasis (VVC): Drug Resistance Rising VVC is a common gynecological infection with thirteen million cases occurring in the US every year, resulting in 5 to 10 million physician visits. Seventy-five percent of all women will experience a VVC episode in their lifetime and 5% will experience recurrent or chronic VVC (³4 episodes/year). The overall VVC market size is almost $6 billion per year. Standard prescription-based therapies are imidazole-based drugs. Infections that do not respond to treatment with this class of drugs are becoming more common, especially in HIV-infected women receiving long-term antifungal therapy. A disadvantage of current therapies is that none are fungicidal agents, directly killing Candida fungi. The azole drugs are all fungistatic agents that simply reduce the replication of the fungi and the woman must rely on her own immune system to control the fungal burden. In addition, azole-resistant Candida species complicate therapy and prolonged exposure to drugs like fluconazole can shift the predominant vaginal yeast from C. albicans to more intrinsically azole-resistant species. There has been a recent epidemiological shift to non-C. albicans strains being the cause of infection. In the early 1990's, Candida albicans accounted for more than 80% of all yeast infections while today, more than 40% is due to non-C. albicans isolates. CZEN 002 is well positioned to effectively treat VVC, especially in patients with chronic VVC or with azole-resistant C. albicans infections. Topical Fungal Infections: High Prevalence Topical fungal infections are a common occurrence and every year approximately 33 million cases of superficial dermatophyte infections occur in the US. Some of the most frequent types are: tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). Tinea unguium (nail infection) affects 1 to 3% of the US population. Use of CZEN 002 to treat topical fungal infections is a logical extension of the VVC indication. Both applications target fungal agents using the existing CZEN 002 topical formulation. Atopic Dermatitis: High Unmet Medical Need in Large Population Atopic dermatitis, often called eczema, is a chronic disease characterized by inflammation of the skin which becomes extremely itchy, red, swollen, crusty and scaly. Atopic dermatitis is a very common disease and accounts for 10 to 20% of all dermatology visits. Approximately 20% of children experience symptoms of atopic dermatitis and more than 15 million adults in the United States have the disease. It is estimated that greater than $1 billion per year is spent on atopic dermatitis treatments. The incessant itch and work loss in adult life is a great burden. The VVC and pruritus clinical studies demonstrated the anti-itch properties of the Zengen peptides. The CZEN 002 topical formulation developed for the VVC application can be leveraged to pursue the large opportunity in atopic dermatitis. Back to top September 06, 2005 Use of a polypeptide for treatment of pruritis in animals. This patent, derived from Zengen's original studies on inflammation and itch in humans, has opened a new treatment for control of pruritis in companion and production animals. This technology is open for partnering. May 03, 2005 Antimicrobial amino acid sequences derived from alpha melanocyte stimulating hormone. The novel molecules covered under this patent have potent effects against fungal infection. This technology is open to partnering. May 01, 2005 Use of KPV tri-peptide for dermatological disorders. This patent forms the basis for multiple clinical applications currently under development. October 12, 2004 Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus. This Zengen technology is available for licensure. October 05, 2004 A uro-genital treatment system patent protects Zengen technologies for vaginal yeast infection applications. Zengen plans to out-license this technology after further progress of the Phase IIb trial. August 24, 2004 A compound method of treatment for fungal pathologies of the oral cavity. This application of Zengen's technologies is also open for license or other forms of partnering. Back to top Please send partnering or licensing inquiries to: infozengen. Or contact: Lipton, PhD President and Chief Executive Officer Phone: (818) 887-8688 Fax: (818) 887-3883 Email: jliptonzengen Back to top © COPYRIGHT ZENGEN, INC. | Website Maintained & Hosted by Majestic Imaging. > > Melanocyte stimulating hormone Dr. Shoemaker is the one I know tests his > patients for it. So far it is not available in the US. - a > > > > > > There was an article about the drug being developed by Palatin Technologies > (PT-141) to enhance sexual functioning in New York Magazine: > > http://newyorkmetro.com/lifestyle/sex/annual/2005/15061/ > > > > alpha MSH replacement medicine, legally obtained in other countries, still > not approved by the FDA. > > Called Melanotan it is supposed to prevent skin cancer, elevate blood > levels of MSH (It is made by the Australian Co., Epi Tan) and in the case of > Melanotan II to act as a sort of Viagra in men. (This is made by the NJ > firmof Palatin Technologies) > Quote
Guest guest Posted February 28, 2007 Report Posted February 28, 2007 Unless things have changed since I last had this discussion with the doctor who knows these things, MSH replacement is not available. Using CSM to get the toxins out and treating staph in the nose can help it to increase over time. Mine went up a teeny bit. - --- In , " Bjerring " <jamesbj@...> wrote: > > If you get tested and find that you're low in MSH, is there a treatment? Can MSH be supplemented or otherwise increased in any way? Thanks. > > Quote
Guest guest Posted February 28, 2007 Report Posted February 28, 2007 They sell it in Australia - for people who want to improve their tans. (do a search on Melanotan 2) A company in the US is working on a version of a nasal spray MSH-like compound that they want to market as an aphrodisiac. I don't know the status on that, but it apparently dramatically increases many people's sex drives. (As we all know, low MSH is very bad for your sex drive..) Perhaps the reason they are having trouble is that then, when this wonder aprodisiac for both sexes becomes available, many people will realize their MSH is low and has been low for years.. because of what we are fighting, and get angry about it? I don't know. These things are very political. Quote
Guest guest Posted March 1, 2007 Report Posted March 1, 2007 , I believe Dr.Shoemaker had mentioned that the FDA will not approve MSH suppliment. I don't remember if it is for this mold exposure or other illnesses. But he did say that if they did approve it it would be very expensive. KC --- In , " Bjerring " <jamesbj@...> wrote: > > If you get tested and find that you're low in MSH, is there a treatment? Can MSH be supplemented or otherwise increased in any way? Thanks. > > > > From: mhbarnes_99 > > Sent: Wednesday, February 28, 2007 6:37 AM > Subject: [] Re: Sick Buildings and Reflux - Is this the causal link? > > > My understanding is that low MSH does contribute to these problems > because it's the hormone that controls the secretion of other hormones, > thus your intestines don't have the levels of hormones that they need > to rebuild the lining properly, so you get all sorts of GI issues with > low MSH. That kinda shows up in the Biotoxin pathway diagram in Mold > Warriors. And, it is true that the largest immune function in our > bodies is in our GI tract (I've read anywhere from 60-80%), thus when > you GI tract is unhealthy, you're immune system is underfunctioning and > I think this is what sets the stage for all these other opportunistic > infections that we seem to collect and I would say definitely > contributes to the imbalances like candida, parasites etc. that many of > us have. > > Here's a link that has a discussion of some comprehensive links on the > role of MSH and the gut: > http://www.anapsid.org/cnd/diffdx/msh.html > > B. > > --- In , " " <smarshwar@> wrote: > > > > Does anyone know if low MSH from mold exposure contributes to these > > digestive problems? > > > > - > > > > --- In , " barb1283 " <barb1283@> wrote: > > > > > > This is from the latest ad on some yogurt but I believe it is true > > > since it makes alot of sense, that 75% of your immune system is in > > > your digestive tract. The downward spiral in my health about 2 > years > > > before cancer started with some medicine that ruined my throat and > > > digestive tract. > > > > > > > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.